Summary & Overview
HCPCS J0681: Injection, Ceftobiprole Medocaril Sodium, 3 mg
HCPCS Level II code J0681 represents the injectable drug ceftobiprole medocaril sodium, 3 mg, and is used to bill for the supply or administration of this parenteral antimicrobial. This code is important for hospitals and infusion providers that administer advanced-spectrum intravenous antibiotics and for payers managing coverage of high-cost specialty antimicrobials. Nationally, accurate use of J0681 affects drug inventory accounting, billing compliance, and payer adjudication for inpatient and outpatient infusion services.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service setting, common modifiers associated with HCPCS drug billing, and what to expect in claims workflows. The publication covers benchmarking and reimbursement context where available, policy and coverage considerations relevant to payers, and guidance on documentation elements typically required to support use of the code. Data not available in the input will be noted as such for any missing benchmark or claims-specific fields.
Billing Code Overview
HCPCS Level II code J0681 describes the injectable antimicrobial ceftobiprole medocaril sodium, supplied in a 3 mg unit. The code is used to report administration of this specific antibiotic formulation when billed separately as a drug or biological.
Service type: Injectable medication administration / drug supply
Typical site of service: Hospital inpatient or outpatient infusion center, including settings where parenteral antibiotics are administered under medical supervision.
Clinical & Coding Specifications
Clinical Context
A 68-year-old hospitalized patient with hospital-acquired pneumonia and risk factors for multi-drug resistant Gram-positive organisms is prescribed intravenous ceftobiprole medocaril. The drug is administered as an inpatient parenteral infusion by hospital nursing staff under an infectious disease or hospitalist treatment plan. The clinical workflow includes order entry by the prescribing physician (often an infectious disease specialist or hospitalist), pharmacy verification and compounding of the J0681 vial strength into the appropriate infusion bag, bedside administration by a registered nurse, infusion monitoring for adverse reactions, and documentation in the electronic health record. Typical sites of service are the inpatient acute care unit, intensive care unit, or an observation unit when given for severe complicated skin/soft tissue infections or hospital-acquired/ventilator-associated pneumonia. The patient scenario can include renal function assessment for dosing adjustments, cultures obtained prior to initiation, daily review of antimicrobial therapy, and documentation of indication and duration in the medication administration record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard use when no other modifier applies |
22 | Increased procedural services | Rarely used; if unusually complex preparation or compounding required beyond typical